Madrigal Pharmaceuticals (MDGL) Capital Expenditures (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Capital Expenditures data on file, last reported at $3.8 million in Q1 2026.

• On a quarterly basis, Capital Expenditures changed N/A year-over-year to $3.8 million in Q1 2026; TTM through Mar 2026 was $4.3 million, a 290.59% increase from a year earlier, with the FY2025 full-year figure at $467000.0, down 68.06% from the prior year.
• Capital Expenditures for Q1 2026 stood at $3.8 million, up from -$261000.0 in the prior quarter.
• Over the last five years, Capital Expenditures for MDGL reached as high as $3.8 million in Q1 2026 and fell as low as -$488000.0 in Q3 2024.
• Historically, Capital Expenditures has averaged $498266.7 across 5 years, with a median of $103000.0 in 2022.
• Across the five-year window, Capital Expenditures surged 5050.0% in 2022 and plunged 243.95% in 2024, its largest moves.
• Year by year, Capital Expenditures stood at $29000.0 in 2022, then surged by 3472.41% to $1.0 million in 2023, then soared by 41.12% to $1.5 million in 2024, then slumped by 117.85% to -$261000.0 in 2025, then soared by 1574.71% to $3.8 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $3.8 million in Q1 2026, -$261000.0 in Q4 2025, and $728000.0 in Q3 2025.